Literature DB >> 3042871

Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant.

W R McCabe1, A DeMaria, H Berberich, M A Johns.   

Abstract

We evaluated the immunoglobulin class responsible for the protective activity in serum obtained from humans and rabbits after immunization with the R595 (Re chemotype) mutant of Salmonella minnesota. Whole serum obtained before immunization and the IgG and IgM fractions failed to protect mice against lethal challenge with viable Klebsiella pneumoniae or Morganella morganii or with Salmonella typhi lipopolysaccharide (LPS). The protective activity of postimmunization serum resided solely in IgM antibody, whereas IgG antibody exhibited no protective activity. IgM antibody to the Re mutant was protective against bacterial challenge with both test strains of bacteria and S. typhi LPS. IgM antibody, at approximately the same concentration present in postimmunization serum, increased the LD50 of K. pneumoniae from less than 8.0 x 10(2) to greater than 2.0 x 10(4). These findings indicate that commercially prepared human IgG with high titers of antibody to antigens of the core portion of LPS would have little clinical utility.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042871     DOI: 10.1093/infdis/158.2.291

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum.

Authors:  J Hellman; P M Loiselle; M M Tehan; J E Allaire; L A Boyle; J T Kurnick; D M Andrews; K Sik Kim; H S Warren
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  Characterization of the epitope specificity of murine monoclonal antibodies directed against lipid A.

Authors:  H M Kuhn; L Brade; B J Appelmelk; S Kusumoto; E T Rietschel; H Brade
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

3.  Monoclonal antibodies in sepsis and septic shock.

Authors:  C J Hinds
Journal:  BMJ       Date:  1992-01-18

4.  Passive immunization to outer membrane proteins MLP and PAL does not protect mice from sepsis.

Authors:  Catherine H Valentine; Judith Hellman; Laura K Beasley-Topliffe; Aranya Bagchi; H Shaw Warren
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

Review 5.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

6.  Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid.

Authors:  Aamir Ali; So J An; Changfa Cui; Abdul Haque; Rodney Carbis
Journal:  Hum Vaccin Immunother       Date:  2014-03-06       Impact factor: 3.452

7.  Use of an immunoglobulin M containing preparation for treatment of two hypogammaglobulinemic patients with persistent Campylobacter jejuni infection.

Authors:  J C Borleffs; J F Schellekens; E Brouwer; M Rozenberg-Arska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-10       Impact factor: 3.267

8.  Comparative virulence of blood and stool isolates of Shigella sonnei.

Authors:  C Seymour; H M Crowe; M E Wilson
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

9.  Anti-idiotypic immunization provides protection against lethal endotoxaemia in BALB/c mice.

Authors:  J J Cornelissen; K Maassen; L van Emst; P M Weers; M Harmsen; B J Benaissa-Trouw; T A Oosterlaken; C A Kraaijeveld; J Verhoef
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

10.  Cross-reactivity of monoclonal antibodies and sera directed against lipid A and lipopolysaccharides.

Authors:  H M Kuhn
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.